ストックスクリーナーアプリを入手
1.64
7.19%
0.11
アフターアワーズ：
1.62
-0.02
-1.22%
前日終値:
$1.53
開ける：
$1.53
24時間の取引高:
815.30K
Relative Volume:
0.50
時価総額：
$45.89M
収益：
-
当期純損益:
$-64.47M
株価収益率:
-0.2651
EPS:
-6.1852
ネットキャッシュフロー:
$-52.33M
1週間 パフォーマンス:
+6.49%
1か月 パフォーマンス:
-6.82%
6か月 パフォーマンス:
-47.94%
1年 パフォーマンス:
-71.08%
1日の値動き範囲:
$1.515
$1.65
1週間の範囲:
$1.49
$1.65
52週間の値動き範囲:
$1.39
$7.19
Jasper Therapeutics Inc Stock (JSPR) Company Profile
名前
Jasper Therapeutics Inc
セクター
電話
(650) 549-1400
住所
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
JSPR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
1.64 | 42.82M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | 開始されました | Rodman & Renshaw | Buy |
| 2025-07-08 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | 開始されました | UBS | Buy |
| 2024-12-06 | 開始されました | BMO Capital Markets | Outperform |
| 2024-09-09 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-08 | 開始されました | BTIG Research | Buy |
| 2024-06-27 | 開始されました | Stifel | Buy |
| 2024-05-06 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-03 | 開始されました | Evercore ISI | Outperform |
| 2024-03-28 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-03-18 | 開始されました | TD Cowen | Outperform |
| 2023-08-11 | 開始されました | CapitalOne | Overweight |
| 2022-02-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-11-08 | 開始されました | Credit Suisse | Outperform |
| 2021-10-21 | 開始されました | William Blair | Outperform |
| 2021-10-20 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-13 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Jasper Therapeutics Inc (JSPR) 最新ニュース
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect - ACCESS Newswire
Jasper Therapeutics (NASDAQ:JSPR) Now Covered by Analysts at Rodman & Renshaw - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Reach Out - ACCESS Newswire
Rodman & Renshaw initiates Jasper Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Reach Out - ACCESS Newswire
RBC Capital Keeps Their Hold Rating on Jasper Therapeutics (JSPR) - The Globe and Mail
HOKA Trail Shoe Guide: Is Jasper Therapeutics Inc. Equity Warrant stock attractive for long term wealth buildingBest Sellers Snapshot & walk-ready comfort choices - Улправда
Jasper Therapeutics reports updated data from briquilimab studies - Yahoo Finance
Jasper Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Companies Like Jasper Therapeutics (NASDAQ:JSPR) Could Be Quite Risky - Sahm
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria - Sahm
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth - Sahm
Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Stockholders to Connect - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition By Investing.com - Investing.com Nigeria
Jasper Therapeutics Reports Strong Briquilimab Data in Urticaria - TipRanks
Jasper Therapeutics Reports Positive Data from Briquilimab Studies - TradingView — Track All Markets
Jasper Therapeutics stock rises after leadership changes By Investing.com - Investing.com India
Jasper Therapeutics stock rises after leadership changes - Investing.com
Jasper Therapeutics appoints Jeet Mahal as CEO in leadership transition - Investing.com
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of ... - Bluefield Daily Telegraph
Jasper Therapeutics, Inc. Announces Executive Changes - marketscreener.com
What analysts say about Jasper Therapeutics Inc stockTop Performing Stocks & Low Risk Trading Alerts - earlytimes.in
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out - ACCESS Newswire
2025-12-28 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Jasper Therapeutics, Inc. (JSPR) And Encourages Shareholders to Reach Out | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Earnings Notes - Trefis
Jasper Therapeutics (JSPR) Price Target Decreased by 15.25% to 13.09 - MSN
Evercore ISI Remains a Buy on Jasper Therapeutics (JSPR) - The Globe and Mail
2025-12-18 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Jasper Therapeutics, Inc. (JSPR) And Encourages Investors to Connect | NDAQ:JSPR | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Jasper Therapeutics, Inc. (JSPR) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Jasper Therapeutics (NASDAQ:JSPR) Stock Price Down 7.3% – Time to Sell? - Defense World
Penny Stocks To Watch NowDecember 2nd - MarketBeat
JSPR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Jasper’s Stock Is In The Basement, But The Bet Is Binary - Finimize
Jasper Therapeutics, Inc. (JSPR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Reports Positive Phase 1b Study Results - MSN
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jasper Therapeutics (JSPR) and Azitra Inc (AZTR) - The Globe and Mail
Jasper Therapeutics stock maintains Market Outperform rating at Citizens By Investing.com - Investing.com Canada
Jasper Therapeutics’ Briquilimab Program Shines Amid Financial Losses - StocksToTrade
Jasper Therapeutics, Inc. (JSPR) Stock: Surges as New Asthma Trial Data Shows Promising Results - parameter.io
Jasper Therapeutics’ Briquilimab: Stepping Up? - StocksToTrade
Can Jasper Therapeutics Deliver on New Studies? - timothysykes.com
$1 Stocks to Watch: JSPR, FTEL, BYND, TOON December 2025 More Inside - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Jasper Therapeutics, Inc. (JSPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Jasper Therapeutics Inc (JSPR) 財務データ
収益
当期純利益
現金流量
EPS
2.09%
0.48%
大文字化:
|
ボリューム (24 時間):